Phase 1/2a for Safety, PK and PD of SQY51 in Paediatric and Adult Patients Duchenne Muscular Dystrophy
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a, monocentric, open label study to evaluate the safety, pharmacokinetics,
and pharmacodynamics of SQY51 in patients with Duchenne muscular dystrophy